Index Ventures III (Delaware) L.P.

CIK 1402023 · last filed 2014-02-13

Index Ventures III (Delaware) L.P. is a corporate insider who has filed 3 SEC Form 4 insider transactions across 2 companies since 2010. The most recent filing, for EGLT, was dated Feb 13, 2014. Across all open-market trades the lifetime net is +$10.7M, making them a net buyer over the disclosed history. The firm reports its address in Bridgewater, NJ. 8 SEC filings were submitted jointly with Index Venture Associates III Ltd.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Disclosed Exposure

$0

Companies

2

Total Filings

3

Lifetime Open-Market Net

$10.73M

Filer Profile

Reported Address

C/O AEGERION PHARMACEUTICALS, INC.
1140 ROUTE 22 EAST, SUITE 304
BRIDGEWATER, NJ 08807

Phone

(908) 704-1300

State of Incorporation

Related Filers

Index Venture Associates III Ltd — 8 joint filings, latest 2014-02-13

Yucca Partners L.P. Jersey Branch — 5 joint filings, latest 2012-02-01

INDEX VENTURES LIFE VI (JERSEY) L.P. — 3 joint filings, latest 2014-02-13

(Jersey) SLP Yucca — 3 joint filings, latest 2014-02-13

Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.

Symbol	Role	Shares	Price	Disclosed Exposure	Lifetime OM Net	Filings	Latest Filed
Zyla Life Sciences (EGLT) Delisted	10%+ Owner	11,636	—	—	$0	1	2014-02-13
Aegerion Pharmaceuticals, Inc. (AEGR) Delisted	10%+ Owner	2,081,827	—	—	$10.73M	2	2012-02-01

Recent Filings

3 filings

Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.

Filed	Symbol	Action	Net Shares	Net $	Link
2014-02-13	Zyla Life Sciences (EGLT) Delisted	Mixed	+11,828,868	$30.58M	EDGAR
2012-02-01	Aegerion Pharmaceuticals, Inc. (AEGR) Delisted	Sell (S)	−250,000	-$4.27M	EDGAR
2010-10-27	Aegerion Pharmaceuticals, Inc. (AEGR) Delisted	Mixed	+15,209,930	$48.48M	EDGAR

Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.